SCHEMBL2548229

SCHEMBL2548229

O=C1NC(=O)C2C3CCC(O3)C12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 5/20 0.56
PPM1B O75688 5/20 0.56
LMNA P02545 4/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
KDM4E B2RXH2 3/20 0.56
GMNN O75496 3/20 0.56
TFPI2 P48307 3/20 0.56
PMP22 Q01453 3/20 0.56
NFKB1 P19838 3/20 0.56
THPO P40225 3/20 0.56
RAB9A P51151 3/20 0.56
PPP1CC P36873 2/20 0.56
PPP5C P53041 2/20 0.56
PPP1CA P62136 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
CYP2D6 P10635 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.36
TSHR P16473 2/20 0.35
CYP3A4 P08684 3/20 0.30
MAPK1 P28482 3/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14381277 1.00 TP53 (0.56) TP53PPM1BLMNASMN1; SMN2KDM4E
SCHEMBL17773447 1.00 TP53 (0.56) TP53PPM1BLMNASMN1; SMN2KDM4E
SCHEMBL13311452 1.00 TP53 (0.56) TP53PPM1BLMNASMN1; SMN2KDM4E
Demethyl-Cantharidin SCHEMBL19318920 0.72 TP53 (1.00) TP53PPM1BLMNASMN1; SMN2KDM4E
Demethyl-Cantharidin SCHEMBL9675442 0.72 TP53 (1.00) TP53PPM1BLMNASMN1; SMN2KDM4E
Demethyl-Cantharidin SCHEMBL3195020 0.72 TP53 (1.00) TP53PPM1BLMNASMN1; SMN2KDM4E
SCHEMBL2120400 0.72 PPM1B (0.56) TP53PPM1BLMNASMN1; SMN2KDM4E
Demethyl-Cantharidin SCHEMBL177729 0.72 TP53 (1.00) TP53PPM1BLMNASMN1; SMN2KDM4E
SCHEMBL13556829 0.72 PPM1B (0.56) TP53PPM1BLMNASMN1; SMN2KDM4E
SCHEMBL407914 0.72 PPM1B (0.56) TP53PPM1BLMNASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137294-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS GENETIC TECHNOLOGIES LIMITED (AU) 2010-06-03 US claimed
EP-2086534-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS Genetic Technologies Limited (AU) 2009-08-12 EP claimed
WO-2008058342-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS GENETIC TECHNOLOGIES LIMITED (AU) 2008-05-22 WO claimed
US-20240327448-A1 LITHIUM REAGENTS AND THEIR USES IN SOLID PHASE SYNTHESIS OLIX US, INC. 2024-10-03 US disclosed
US-11807618-B2 Thiophene derivatives as antiviral agents ENYO PHARMA (FR) 2023-11-07 US disclosed
EP-3122757-B1 CHARGED LINKERS AND THEIR USES FOR CONJUGATION HANGZHOU DAC BIOTECH CO LTD (CN) 2023-09-06 EP disclosed
US-20220213053-A1 THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS ENYO PHARMA (FR) 2022-07-07 US disclosed
US-11279683-B2 Thiophene derivatives as antiviral agents ENYO PHARMA (FR) 2022-03-22 US disclosed
US-10696699-B2 Charged linkers and their uses for conjugation HANGZHOU DAC BIOTECH CO., LTD. (CN) 2020-06-30 US disclosed
US-10696700-B2 Charged linkers and their uses for conjugation HANGZHOU DAC BIOTECH CO., LTD. (CN) 2020-06-30 US disclosed
US-10683314-B2 Charged linkers and their uses for conjugation HANGZHOU DAC BIOTECH CO., LTD. (CN) 2020-06-16 US disclosed
EP-1339716-B1 LACTAM-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES BAYER HEALTHCARE AG (DE) 2004-11-03 EP disclosed
WO-2004009589-A1 NOVEL 2,5-DISUBSTITUTED PYRIMIDINE DERIVATIVES BAYER HEALTHCARE AG (DE) 2004-01-29 WO disclosed
EP-1339716-A1 NOVEL LACTAME-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES Bayer Aktiengesellschaft (DE) 2003-09-03 EP disclosed
EP-1214325-A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) NOVO NORDISK A/S (DK) 2002-06-19 EP disclosed
EP-1214060-A2 METHOD OF INHIBITING PROTEIN TYROSINE PHOSPHATASE 1B AND/OR T-CELL PROTEIN TYROSINE PHOSPHATASE AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 NOVO NORDISK A/S (DK) 2002-06-19 EP disclosed
WO-2002042299-A1 NOVEL LACTAME-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2002-05-30 WO disclosed
WO-2001019831-A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) NOVO NORDISK A/S (DK) 2001-03-22 WO disclosed
WO-2001017516-A2 METHOD OF INHIBITING PROTEIN TYROSINE PHOSPHATASE 1B AND/OR T-CELL PROTEIN TYROSINE PHOSPHATASE AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 NOVO NORDISK A/S (DK) 2001-03-15 WO disclosed
US-4057432-A PHOTOGRAPHIC COUPLERS KONISHIROKU PHOTO INDUSTRY CO., LTD. (JA) 1977-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10696700-B2 Charged linkers and their uses for conjugation PHOSPHO1, PCTP, CD2BP2 TP53 784/4885PPM1B 1261/4885LMNA 3457/4885
US-20220213053-A1 THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS MAVS, EIF2AK2, IRF3 TP53 1353/4885PPM1B 738/4885LMNA 4815/4885
US-20100137294-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS PPP1R10, TASP1, PPP5C TP53 1847/4885PPM1B 30/4885LMNA 4332/4885
US-20240327448-A1 LITHIUM REAGENTS AND THEIR USES IN SOLID PHASE SYNTHESIS POLRMT, NSUN2, RNGTT TP53 1944/4885PPM1B 3970/4885LMNA 564/4885
US-11279683-B2 Thiophene derivatives as antiviral agents MAVS, EIF2AK2, IRF3 TP53 2656/4885PPM1B 786/4885LMNA 4796/4885
US-10683314-B2 Charged linkers and their uses for conjugation PHOSPHO1, PCTP, CD2BP2 TP53 784/4885PPM1B 1261/4885LMNA 3457/4885
US-11807618-B2 Thiophene derivatives as antiviral agents MAVS, EIF2AK2, IRF3 TP53 1353/4885PPM1B 738/4885LMNA 4815/4885
US-10696699-B2 Charged linkers and their uses for conjugation PHOSPHO1, PCTP, CD2BP2 TP53 784/4885PPM1B 1261/4885LMNA 3457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.